Semaglutide and Kidney Health
In the FLOW trial, once-weekly semaglutide lowered major kidney disease events by 24% in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
Semaglutide
Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
Semaglutide and NT-proBNP in Obesity-Related HFpEF (STEP-HFpEF)
A prespecified secondary analysis of the STEP-HFpEF programme found that once-weekly semaglutide 2.4 mg lowered NT-proBNP and produced larger symptom gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
SURPASS-2 Post Hoc: Tirzepatide vs Semaglutide on Beta-Cell Function and Insulin Sensitivity
A post hoc analysis of the SURPASS-2 phase 3 trial comparing tirzepatide and semaglutide on HOMA2 markers of beta-cell function and insulin sensitivity in type 2 diabetes. PICO summary and expert commentary.
STEP-HFpEF Pooled Analysis
Pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials of semaglutide 2.4 mg in obesity-related HFpEF, with PICO summary and expert commentary.
Semaglutide and Heart Failure in Diabetes
STEP-HFpEF DM: once-weekly semaglutide 2.4 mg improved symptoms, weight, and exercise capacity versus placebo in obese, diabetic patients with HFpEF. PICO summary and expert commentary.
ESSENCE Trial: Baseline Characteristics and Design (Semaglutide 2.4 mg in MASH)
Design and baseline characteristics of the phase 3 ESSENCE trial of weekly semaglutide 2.4 mg in 800 participants with biopsy-proven MASH and fibrosis stage 2 or 3, with no efficacy results reported yet. PICO summary and expert commentary.
Semaglutide and Primary Prevention of Diabetic Kidney Disease (SUSTAIN 6 Post Hoc)
A post hoc analysis of SUSTAIN 6 suggesting once-weekly semaglutide lowered new-onset diabetic kidney disease in type 2 diabetes. PICO summary and expert commentary.
Semaglutide Efficacy Across Baseline Subgroups: A Post Hoc Analysis of SUSTAIN China
A post hoc analysis of the SUSTAIN China trial found that the glycaemic efficacy of once-weekly semaglutide versus sitagliptin was consistent across most baseline subgroups. PICO summary and expert commentary.
IcoSema Pharmacokinetics: Insulin Icodec and Semaglutide Fixed-Ratio Combination Versus Separate Administration
A phase 1 crossover study of the IcoSema fixed-ratio combination of insulin icodec and semaglutide reports unchanged icodec exposure but a higher, earlier semaglutide peak versus separate injections. PICO summary and expert commentary.
Psychiatric Safety of Semaglutide 2.4 mg for Weight Management: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials
Post hoc analysis of the STEP 1, 2, 3, and 5 trials finds semaglutide 2.4 mg did not increase depression or suicidal ideation versus placebo in people without major psychopathology. PICO summary and expert commentary.